<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791881</url>
  </required_header>
  <id_info>
    <org_study_id>HG-06-01</org_study_id>
    <nct_id>NCT01791881</nct_id>
  </id_info>
  <brief_title>Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of &quot;Hugeltox Inj.&quot; in Essential Blepharospasm</brief_title>
  <official_title>Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of &quot;Hugeltox Inj.&quot; In Essential Blepharospasm Running Parallel With Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of Hugel-Tox (Botulinum toxin A, Hugel, Korea) against
      Botox in the treatment of Essential Blepharospasm and to get a regulatory approval from KFDA
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with an improvement more than one Grade of Severity of Spasm (by Scott's Method)</measure>
    <time_frame>at 4 weeks post-injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(1) Duration of action days</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Grades of Severity of Spasm (by Scott's Method), Functional Visual Status</measure>
    <time_frame>at four weeks post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(3) Rate of patients with a Grade-0 or Grade-1 of Severity Spasm (by Scott's Method)</measure>
    <time_frame>at four weeks post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(4) Rate of patients with an improvement more than two Grade of Severity of Spasm (by Scott's Method)</measure>
    <time_frame>at four weeks post-injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Essential Blepharospasm</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin type A(Botox®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Hugeltox)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A(Hugeltox)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hugeltox</intervention_name>
    <description>1.25U~2.5U/site, Maximum dosage 12.5U~60U/person</description>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_label>Botulinum toxin type A(Hugeltox)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A(Botox®)</intervention_name>
    <description>1.25U~2.5U/site, Maximum dosage 12.5U~60U/person</description>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_label>Botulinum toxin type A(Hugeltox)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult between ages 18 and 75 years

          -  All patients, diagnosed of essential blepharospasm, with Grade 2~4 of Severity of
             Spmasm (by Scott's Method)

        Exclusion Criteria:

          -  Patients have undergone surgical surgery to treat blepharospmasm like myectomy or
             neurectomy

          -  Patients with hypersensitivity history to botulinum toxin products previously

          -  Patients with secondary blepharomspasm

          -  Patients with hemifacialspasm

          -  Patients with treatment following drugs ; Anticonvulsants, tranquilizers, narcotics,
             aminoglycoside antibiotics, muscle relaxtants like baclofen etc., blockers of
             parasympathetic nervous system, levodopa

          -  Patients with previous injection of other botulinum toxin products in 3 months

          -  Patients with any other significant neuromuscular disease like Myasthenia gravis

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Duck Kim, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cha Hospital</name>
      <address>
        <city>Bundang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital - Bundang</name>
      <address>
        <city>Bundang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Youngnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim's eye hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University, Seoul, St.Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The catholic university, Yeouido, St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeonsei University, Severance hospital - Gangnam</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

